141 related articles for article (PubMed ID: 18452095)
1. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
Leleu X; Moreau AS; Weller E; Roccaro AM; Coiteux V; Manning R; Nelson M; Leduc R; Robu D; Dupire S; Hatjiharissi E; Burwick N; Darre S; Hennache B; Treon SP; Facon T; Gertz MA; Ghobrial IM
Leuk Lymphoma; 2008 Jun; 49(6):1104-7. PubMed ID: 18452095
[TBL] [Abstract][Full Text] [Related]
2. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Rivkin SE; Roodman GD; Tuscano JM; Shurafa M; Kyle RA; Crowley JJ; Barlogie B
Blood; 2001 Jul; 98(1):41-8. PubMed ID: 11418461
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia.
Moreau AS; Sebti Y; Duhamel A; Roccaro AM; Coiteux V; Gastinne T; Le Friec G; Burwick N; Amiot L; Ho AW; Poulain S; Hennache B; Hunter ZR; Dessaint JP; Ghobrial IM; Treon SP; Facon T; Zorn E; Leleu X
Eur J Haematol; 2008 Jun; 80(6):503-9. PubMed ID: 18331603
[TBL] [Abstract][Full Text] [Related]
5. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
[TBL] [Abstract][Full Text] [Related]
6. Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
[TBL] [Abstract][Full Text] [Related]
7. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
Leleu X; Xie W; Bagshaw M; Banwait R; Leduc R; Roper N; Weller E; Ghobrial IM
Clin Cancer Res; 2011 May; 17(9):3013-8. PubMed ID: 21415221
[TBL] [Abstract][Full Text] [Related]
8. The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.
Klein CJ; Moon JS; Mauermann ML; Zeldenrust SR; Wu Y; Dispenzieri A; Dyck PJ
Can J Neurol Sci; 2011 Mar; 38(2):289-95. PubMed ID: 21320835
[TBL] [Abstract][Full Text] [Related]
9. Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery.
Kriangkum J; Taylor BJ; Strachan E; Mant MJ; Reiman T; Belch AR; Pilarski LM
Blood; 2006 Apr; 107(7):2920-7. PubMed ID: 16317092
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin heavy chain sequence analysis in Waldenstrom's macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance.
Rollett RA; Wilkinson EJ; Gonzalez D; Fenton JA; Short MA; Evans PA; Rawstron AC; Owen RG
Clin Lymphoma Myeloma; 2006 Jul; 7(1):70-2. PubMed ID: 16879773
[TBL] [Abstract][Full Text] [Related]
11. The role of high serum CXCL13 level in Waldenström macroglobulinemia.
Wu YY; Cai H; Zhao AL; Zhang L; Zhou DB; Cao XX; Li J
Leuk Res; 2019 Jun; 81():50-55. PubMed ID: 31015152
[TBL] [Abstract][Full Text] [Related]
12. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J
Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
14. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
Varettoni M; Zibellini S; Capello D; Arcaini L; Rossi D; Pascutto C; Rattotti S; Mangiacavalli S; Pochintesta L; Gotti M; Gaidano G; Cazzola M
Leuk Lymphoma; 2013 Nov; 54(11):2485-9. PubMed ID: 23442064
[TBL] [Abstract][Full Text] [Related]
15. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism.
Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S
Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107
[TBL] [Abstract][Full Text] [Related]
16. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
17. Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families.
McMaster ML; Csako G; Giambarresi TR; Vasquez L; Berg M; Saddlemire S; Hulley B; Tucker MA
Clin Cancer Res; 2007 Sep; 13(17):5063-9. PubMed ID: 17785558
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
[TBL] [Abstract][Full Text] [Related]
19. Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.
Zou H; Yang R; Liao ZX; Qin TD; Chen P; Zhang BY; Cao YP; Huang HF
J Clin Lab Anal; 2019 Mar; 33(3):e22827. PubMed ID: 30485557
[TBL] [Abstract][Full Text] [Related]
20. Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.
Grass S; Preuss KD; Wikowicz A; Terpos E; Ziepert M; Nikolaus D; Yang Y; Fadle N; Regitz E; Dimopoulos MA; Treon SP; Hunter ZR; Pfreundschuh M
Blood; 2011 Mar; 117(10):2918-23. PubMed ID: 21220746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
